regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy.

Sector

Professional, Scientific, and Technical Services

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

CEO

Kenneth Mills

regenxbio.com/ →

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance